Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy
Dignitana announces that the Hospital de Clínicas in Montevideo, Uruguay has completed the first stage of a two-year investigational study of DigniCap efficacy in women with breast and ovarian cancer led by Dr. Gabriel Krygier, Director of the Department of Oncology at Hospital de Clínicas.
Dr. Krygier reports the first phase of the study demonstrated a 79 percent success rate, with 19 of the 24 patients using DigniCap Delta retaining more than 50 percent of their hair (65-95 percent). Additionally, two patients lost 50 percent of their hair and three patients discontinued treatment due to cold intolerance during the study.
The Breast Cancer Rapid Resolution Program study shows a direct improvement on the quality of life of cancer patients, Dr. Krygier explained, “It is not only the treatment, the surgery, the chemo, but being able to know that the treatment ends while preserving the hair, which implies dignity in the patient,” he explained. “DigniCap cooled the scalp and, thus, prevented between 65 percent and 95 percent of hair loss in patients with solid tumors receiving chemotherapy.”
In March 2022 Hospital de Clínicas was the first in Latin America to offer the DigniCap Delta Scalp Cooling System to minimize hair loss from chemotherapy, as highlighted by Dr. Krygier in this video. With increased interest and utilization, the hospital purchased a second DigniCap Delta device in October 2023.
The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate and gynecological cancers.
Uruguay has one of the highest incidences of cancer in Latin America, with Breast cancer accounting for 25.4 percent of cancers in women and 12 percent of diagnoses among men and women, the second highest of all cancer types (Globocan 2020).
Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network® (NCCN) and Cancer Australia.
